Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple Turns 50: From Garage Startup to AI Crossroads 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
NEW YORK, Jan. 04, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased shares of ProNAi Therapeutics, Inc. (“ProNAi”) (NASDAQ:DNAI) between July 15, 2015 and June 6, 2016 (the “Class Period”). You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/pronai-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, ProNAi made materially false and misleading statements about the potential and efficacy of its drug product candidate PNT2258 in the company’s public filings, which caused ProNAi’s stock price to be artificially inflated throughout the Class Period, thus harming investors.
On June 6, 2016, ProNAi revealed that the Phase 2 clinical trials of PNT2258 failed to produce sufficient efficacy results to justify continued clinical development of the drug and, thus, ProNAi was suspending clinical development of PNT2258. Following this news, shares of ProNAi fell more than 67 percent.
If you suffered a loss in ProNAi you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
